The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1212
July 4, 2005
View Complete Issue         Table of Contents 2019 
Pegaptanib Sodium (Macugen) for Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pegaptanib Sodium (Macugen) for Macular Degeneration
July 4, 2005 (Issue: 1212)
The FDA has approved pegaptanib sodium (Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved treatment for this condition is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegaptanib Sodium (Macugen) for Macular Degeneration
Article code: 1212c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.